Dabigatran in cardiovascular disease management:A comprehensive review  

作　　者：Ayesha Javed Muhammad Ajmal Aaron Wolfson 

机构地区：[1]Department of Internal Medicine,University of Arizona,Tucson,AZ 85719,United States [2]Department of Cardiology,University of Arizona,Tucson,AZ 85719,United States [3]Department of Cardiology,University of Southern California,Los Angeles,CA 90007,United States

出　　处：《World Journal of Cardiology》2021年第12期710-719,共10页世界心脏病学杂志（英文版）（电子版）

摘　　要：Dabigatran,a direct thrombin inhibitor,has robust data for the treatment of deep venous thrombosis and pulmonary embolism,stroke prevention in non-valvular atrial fibrillation,and the prophylaxis of venous thromboembolism(VTE)after knee and hip replacement.Recent studies have evaluated dabigatran to determine its safety and efficacy in such conditions as VTE in malignancy,coronary artery disease,mechanical and bioprosthetic valves,and antiphospholipid syndrome.This article provides a comprehensive review on the role of dabigatran in various cardiovascular diseases.

关 键 词：DABIGATRAN ANTICOAGULATION THROMBUS BLEEDING Atrial fibrillation Deep venous thrombosis Stroke 

分 类 号：R54[医药卫生—心血管疾病]